Literature DB >> 10202728

Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis.

L M Lenton1, J M Albietz.   

Abstract

BACKGROUND: Strategies to minimize intraoperative ocular surface disturbance and accelerate postoperative ocular surface recovery are an important consideration to the surgeon.
METHODS: Eighteen eyes of 10 patients were randomized to receive intraoperative and postoperative non-preserved balanced salt solution or non-preserved carboxymethylcellulose-based (carmellose) artificial tears. Presence and severity of McMonnies dry eye symptom survey score primary dry eye symptoms, fluorescein break-up time, and rose bengal staining were graded preoperatively and at 1 day, 1 week and 1 month postoperatively. Conjunctival impression cytology of the perilimbal conjunctiva was performed 1 month after surgery to determine goblet cell density.
RESULTS: McMonnies dry eye symptoms were reported more frequently for the balanced salt solution group at 1 day, 1 week, and 1 month after surgery. Fluorescein break-up time was significantly greater in the carmellose-based group at 1 day (P < .01), 1 week (P = .04), and 1 month (P < .01) after surgery. The rose bengal staining score was significantly greater at 1 day (P < .01) and 1 week (P < .01) postoperatively for the balanced salt solution group. Mean goblet cell density for the carmellose-based group at 1 month postoperatively was significantly greater than that for the balanced salt solution group (P < .01).
CONCLUSIONS: Postoperative and intraoperative use of carmellose-based artificial tears resulted in significantly more rapid recovery of the ocular surface after LASIK when compared to balanced salt solution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202728     DOI: 10.3928/1081-597X-19990302-17

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  8 in total

1.  A comparative assessment of the efficacy of carbomer gel and carboxymethyl cellulose containing artificial tears in dry eyes.

Authors:  Qing Xiao; Yanhua Hu; Fei Chen; Xiaomin Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

2.  Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial.

Authors:  Peter A Simmons; Haixia Liu; Cindy Carlisle-Wilcox; Joseph G Vehige
Journal:  Clin Ophthalmol       Date:  2015-04-15

Review 3.  Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease.

Authors:  Antonio José Mateo Orobia; Jorge Saa; Alberto Ollero Lorenzo; José María Herreras
Journal:  Clin Ophthalmol       Date:  2018-03-06

4.  Topical Osmoprotectant for the Management of Postrefractive Surgery-Induced Dry Eye Symptoms: A Randomised Controlled Double-Blind Trial.

Authors:  R M Hazarbassanov; N G T Queiroz-Hazarbassanov; J N Barros; J A P Gomes
Journal:  J Ophthalmol       Date:  2018-02-20       Impact factor: 1.909

5.  A combination of CMC and α-MSH inhibited ROS activated NLRP3 inflammasome in hyperosmolarity stressed HCECs and scopolamine-induced dry eye rats.

Authors:  Ying Lv; Chenchen Chu; Ke Liu; Yusha Ru; Yan Zhang; Xiaoxiao Lu; Yichen Gao; Caijie Zhang; Shaozhen Zhao
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

6.  Investigating the potential benefits of a new artificial tear formulation combining two polymers.

Authors:  Peter A Simmons; Joseph G Vehige
Journal:  Clin Ophthalmol       Date:  2017-09-12

Review 7.  Dry Eye Post-Laser-Assisted In Situ Keratomileusis: Major Review and Latest Updates.

Authors:  Eyal Cohen; Oriel Spierer
Journal:  J Ophthalmol       Date:  2018-01-28       Impact factor: 1.909

8.  Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose.

Authors:  Avi Wallerstein; W Bruce Jackson; Jeffrey Chambers; Amir M Moezzi; Hugh Lin; Peter A Simmons
Journal:  Clin Ophthalmol       Date:  2018-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.